Inflammation, PXR Modification and Drug Disposition
炎症、PXR 修饰和药物处置
基本信息
- 批准号:8463519
- 负责人:
- 金额:$ 30.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-06 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectBiochemicalBiologyCarrier ProteinsCombined Modality TherapyComplexCultured CellsDataDevelopmentDiseaseDrug PrescriptionsEnzymesFeedbackFrequenciesGene TargetingGenesGenetic PolymorphismHDAC3 geneHepaticHepatocyteImmunosuppressionIn VitroIndividualInflammationInflammatoryInflammatory ResponseIntestinesKnowledgeLaboratoriesLigand BindingLigandsLiverLiver diseasesMass Spectrum AnalysisMediatingMetabolismMethodsModelingMolecularNF-kappa BNuclear ReceptorsPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePost-Translational Protein ProcessingPregnanesPreventionProteinsReactionReceptor ActivationRepressionResearch ProposalsRifampinSchemeSignal TransductionSiteTestingTissuesTumor Necrosis Factor-alphaWorkXenobioticsbasecombatcytokinedrug metabolismdrug modificationexperienceimprovedinformation gatheringinnovationinsightnovelnovel therapeuticspreventpromoterprotein complexreceptorresponsesensorsmall moleculeuptake
项目摘要
DESCRIPTION (provided by applicant): The long-term objectives of my laboratory are to improve our understanding of the basic regulatory mechanisms that govern drug disposition and drug metabolism. There is a clear recognition that the frequency of adverse drug reactions (ADRs) is increased in patients affected with an underlying systemic inflammation. In these individuals, variable drug responses are not necessarily related to genetic polymorphisms but are due to the rapid and dramatic reduction in the expression of key genes that encode important drug metabolizing enzymes (DMEs) and drug transporter proteins. In liver, the pregnane x receptor (PXR) is the master- xenobiotic 'sensor'. Ligand-dependent activation of PXR increases the overall uptake, metabolism, transport and eventual elimination of a myriad of xenobiotics and prescription drugs. Based upon strong preliminary data, we hypothesize that the immunosuppressive effects that occur in patients following Rifampicin therapy occurs via the post-translational modification of the PXR protein. We provide evidence that TNFalpha promotes poly-sumoylation of liganded-PXR to feedback repress NF-kappa B-target genes. Aim 1 will define the specific sites of ligand-activated PXR SUMOylation sequentially in vitro, in cultured cells, and then in hepatocytes using a novel and innovative mass spectrometry-based approach. Aim 2 will test the hypothesis that the mechanism of selective repression of the inflammatory response is due to SUMO-modified PXR preventing clearance of nuclear receptor corepressor/NF-kappa B complexes using biochemical methods. Understanding the biochemical details and molecular mechanisms of how PXR is converted from a positive regulator of hepatic DMEs into a transcriptional suppressor of inflammation in liver tissue will provide a new molecular paradigm for understanding drug-mediated repression of the hepatic inflammatory response. New molecular insights regarding the biology of PXR SUMOylation will provide new opportunities to develop novel pharmacological strategies for addressing ADRs, and will eventually help to identify small molecules that will be used to treat inflammatory liver diseases.
描述(由申请人提供):我实验室的长期目标是提高我们对控制药物处置和药物代谢的基本调节机制的理解。有一个明确的认识,即药物不良反应(ADR)的频率增加,受影响的患者与潜在的全身炎症。在这些个体中,可变的药物反应不一定与遗传多态性相关,而是由于编码重要药物代谢酶(DME)和药物转运蛋白的关键基因表达的快速和急剧减少。在肝脏中,胆甾烷X受体(PXR)是异生物质的主“传感器”。PXR的配体依赖性激活增加了大量外源性物质和处方药的总体摄取、代谢、运输和最终消除。基于强有力的初步数据,我们假设利福平治疗后患者的免疫抑制作用是通过PXR蛋白的翻译后修饰发生的。我们提供的证据表明,TNF α促进配体PXR的聚类小泛素化,以反馈抑制NF-κ B靶基因。目的1将确定特定的网站配体激活PXR SUMO化顺序在体外,在培养细胞,然后在肝细胞中使用一种新的和创新的质谱为基础的方法。目的2将使用生物化学方法来检验选择性抑制炎症反应的机制是由于SUMO修饰的PXR阻止核受体辅抑制物/NF-κ B复合物的清除的假设。了解PXR如何从肝DME的正调节因子转化为肝组织炎症的转录抑制因子的生物化学细节和分子机制,将为了解药物介导的肝脏炎症反应抑制提供新的分子范式。关于PXR SUMO化生物学的新分子见解将为开发解决ADR的新药理学策略提供新的机会,并最终有助于确定用于治疗炎症性肝病的小分子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey L Staudinger其他文献
Jeffrey L Staudinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey L Staudinger', 18)}}的其他基金
Inflammation, PXR Modification and Drug Disposition
炎症、PXR 修饰和药物处置
- 批准号:
8662253 - 财政年份:2011
- 资助金额:
$ 30.5万 - 项目类别:
Inflammation, PXR Modification and Drug Disposition
炎症、PXR 修饰和药物处置
- 批准号:
8299482 - 财政年份:2011
- 资助金额:
$ 30.5万 - 项目类别:
Inflammation, PXR Modification and Drug Disposition
炎症、PXR 修饰和药物处置
- 批准号:
8184016 - 财政年份:2011
- 资助金额:
$ 30.5万 - 项目类别:
Cell Signaling, PXR Phosphorylation & Drug Disposition
细胞信号转导、PXR 磷酸化
- 批准号:
7095870 - 财政年份:2005
- 资助金额:
$ 30.5万 - 项目类别:
Cell Signaling, PXR Phosphorylation & Drug Disposition
细胞信号转导、PXR 磷酸化
- 批准号:
7656908 - 财政年份:2005
- 资助金额:
$ 30.5万 - 项目类别:
Cell Signaling, PXR Phosphorylation & Drug Disposition
细胞信号转导、PXR 磷酸化
- 批准号:
7483626 - 财政年份:2005
- 资助金额:
$ 30.5万 - 项目类别:
Cell Signaling, PXR Phosphorylation & Drug Disposition
细胞信号转导、PXR 磷酸化
- 批准号:
7269246 - 财政年份:2005
- 资助金额:
$ 30.5万 - 项目类别:
COBRE: U KS: P5: CRYSTALLIZATION OF PREGNANE X RECEPTOR SPLICE VARIANTS
COBRE:UK KS:P5:妊娠 X 受体剪接变体的结晶
- 批准号:
7171174 - 财政年份:2005
- 资助金额:
$ 30.5万 - 项目类别:
Cell Signaling, PXR Phosphorylation & Drug Disposition
细胞信号转导、PXR 磷酸化
- 批准号:
6926039 - 财政年份:2005
- 资助金额:
$ 30.5万 - 项目类别:
COBRE: U KS: P5: CRYSTALLIZATION OF PREGNANE X RECEPTOR SPLICE VARIANTS
COBRE:UK KS:P5:妊娠 X 受体剪接变体的结晶
- 批准号:
6981851 - 财政年份:2004
- 资助金额:
$ 30.5万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 30.5万 - 项目类别:
Research Grant